Drug Approval | December 28, 2021
Aurobindo to manufacture and market molnupiravir
The drug will be marketed under the brand name Molnaflu
The drug will be marketed under the brand name Molnaflu
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
Subscribe To Our Newsletter & Stay Updated
